Journal
AMERICAN JOURNAL OF TRANSPLANTATION
Volume 19, Issue 9, Pages 2570-2582Publisher
WILEY
DOI: 10.1111/ajt.15352
Keywords
clinical research; practice; complication; infectious; donors and donation; donor evaluation; donors and donation; donor-derived infections; infection and infectious agents - viral; hepatitis B; infection and infectious agents - viral; hepatitis C; infectious disease
Categories
Funding
- Intramural CDC HHS [CC999999] Funding Source: Medline
Ask authors/readers for more resources
We evaluated clinical outcomes among organ recipients with donor-derived hepatitis B virus (HBV) or hepatitis C virus (HCV) infections investigated by CDC from 2014 to 2017 in the United States. We characterized new HBV infections in organ recipients if donors tested negative for total anti-HBc, HBsAg and HBV DNA, and new recipient HCV infections if donors tested negative for anti-HCV and HCV RNA. Donor risk behaviors were abstracted from next-of-kin interviews and medical records. During 2014-2017, seven new recipient HBV infections associated with seven donors were identified; six (86%) recipients survived. At last follow-up, all survivors had functioning grafts and five (83%) had started antiviral therapy. Twenty new recipient HCV infections associated with nine donors were identified; 19 (95%) recipients survived. At last follow-up, 18 (95%) survivors had functioning grafts and 14 (74%) had started antiviral treatment. Combining donor next-of kin interviews and medical records, 11/16 (69%) donors had evidence of injection drug use and all met Public Health Service increased risk donor (IRD) criteria. IRD designation led to early diagnosis of recipient infection, and prompt implementation of therapy, likely reducing the risk of graft failure, liver disease, and death.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available